<DOC>
	<DOCNO>NCT02951156</DOCNO>
	<brief_summary>Study B9991011 multi-center , international , randomize , open label , 2 component ( Phase 1b follow Phase 3 ) , parallel-arm study avelumab combination various agent treatment Relapsed/Refractory ( R/R ) Diffuse Large B-Cell Lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Avelumab In Combination Regimens That Include An Immune Agonist , Epigenetic Modulator , CD20 Antagonist and/or Conventional Chemotherapy Patients With Relapsed Refractory Diffuse Large B-cell Lymphoma ( R/R DLBCL )</brief_title>
	<detailed_description>The target study population Phase 1b/3 registrational study patient R/R DLBCL complete least 2 ( 4 ) line prior rituximab-containing multi-agent chemotherapy , and/or autologous stem cell transplant ( ASCT ) fail , candidate ASCT eligible intensive chemotherapy . Patients ineligible intensive second line chemotherapy must receive least one prior rituximab-containing combination chemotherapy regimen . The study ass safety , efficacy , pharmacokinetics ( PK ) , immunogenicity 3 avelumab-based combination regimen test , collect patient report outcome ( PRO ) data .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Key Relapsed refractory DLBCL follow least 2 line ( maximum 4 line ) prior rituximab contain multiagent chemotherapy may include autologous stem cell transplantation unless patient consider suitable intensive secondline chemotherapy autologous stem cell transplantation . Patients ineligible intensive second line chemotherapy , must receive least one prior rituximabcontaining combination chemotherapy regimen . Patients ineligible intensive second line chemotherapy , must receive least one prior rituximabcontaining combination chemotherapy regimen . Baseline measurable disease least 1 bi dimensional lesion &gt; 1.5cm CT scan FDG avid PET scan . A biopsy ( archived Screening/recent ) collect Screening . At least 18years age ( â‰¥20 year Japan ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . Key Transformed lymphoma Burkitt 's Lymphoma . Active/symptomatic central nervous system ( CNS ) lymphoma base clinical evaluation . Prior organ transplantation include prior allogeneic SCT . Prior therapy anti PD 1 , anti PD L1 , anti PD L2 , anti CD137 , anti cytotoxic T lymphocyte associate antigen 4 ( CTLA 4 ) antibody ( include ipilimumab , tremelimumab antibody , drug specifically target T cell co stimulatory immune checkpoint pathway ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>